The Ets family transcription factor PU.1 and the interferon regulatory factor (IRF)4 and IRF8 regulate gene expression by binding to composite DNA sequences known as Ets/interferon consensus elements. Although all three factors are expressed from the onset of B-cell development, single deficiency of these factors in B-cell progenitors only mildly impacts on bone marrow B lymphopoiesis. Here we tested whether PU.1 cooperates with IRF factors in regulating early B-cell development. Lack of PU.1 and IRF4 resulted in a partial block in development the pre-B-cell stage. The combined deletion of PU.1 and IRF8 reduced recirculating B-cell numbers. Strikingly, all PU.1/IRF4 and~50% of PU.1/IRF8 double deficient mice developed pre-B-cell acute lymphoblastic leukemia (B-ALL) associated with reduced expression of the established B-lineage tumor suppressor genes, Ikaros and Spi-B. These genes are directly regulated by PU.1/IRF4/IRF8, and restoration of Ikaros or Spi-B expression inhibited leukemic cell growth. In summary, we demonstrate that PU.1, IRF4 and IRF8 cooperate to regulate early B-cell development and to prevent pre-B-ALL formation.
INTRODUCTION
The Ets transcription factor PU.1 is a key regulator of hematopoiesis. Biochemical [1] [2] [3] [4] [5] [6] and genome-wide analyses of DNA-binding sites 7, 8 have demonstrated that PU.1 can bind to DNA alone at canonical Ets sites, or together with hematopoietic restricted factors IRF4 and IRF8 at composite Ets-interferon consensus elements (EICE) sites. The functional importance of these biochemical interactions has not been examined.
Germline or conditional deficiency of PU.1 (encoded by Spi1) in hematopoietic stem cells results in the loss of macrophages, granulocytes, dendritic cells, lymphocytes and functional hematopoietic stem cells activity. [9] [10] [11] In contrast, conditional ablation of PU.1 expression in B-cell progenitors only mildly affects B-cell development. 11, 12 Recent evidence suggests that the loss of PU.1 function in B-cell progenitors is compensated for by the related Ets family member Spi-B, as combined deletion of PU.1 and Spi-B in the B-cell lineage impairs B-cell development in the bone marrow (BM). 13 Similar to the redundant function of PU.1 and Spi-B, deletion of either interferon regulatory factor (IRF)4 or IRF8 only mildly affects early B-cell development while double deficiency results in a block at the pre-B-cell stage. [14] [15] [16] [17] PU.1 and IRF8 are both established tumor suppressors in the myeloid lineage, with their loss promoting acute myeloid leukemia and chronic myeloid leukemia, respectively. [18] [19] [20] [21] [22] [23] [24] However their roles in suppressing B-lineage acute lymphoblastic leukemia (B-ALL) are less clear. Rare mutations in SPI1 (PU.1) and IRF8 have been found in human pre-B-ALL 25, 26 and diffuse large B-cell lymphoma, 27 while SPIB expression is reduced in pre-B-ALL carrying the t(12;21) ETV6-RUNX1 translocation. 28 IRF4 has been implicated in several B-cell malignancies, including chronic lymphocytic leukemia 29 and multiple myeloma, 30 and it was recently reported that IRF4 is twofold overexpressed in pediatric pre-B-ALL compared with unfractionated healthy BM. 31 Irf4 − / − mice do not develop pre-B-ALL, but IRF4 deficiency cooperates with oncogenes such as BCR-Abl 32 and c-Myc 33 to promote leukemogenesis in mouse models. Mice lacking both IRF4 and IRF8 initially show more accelerated myelopoiesis, a characteristic of the early stages of chronic myeloid leukemia, but ultimately succumb to pre-B-ALL. 34 Most recently, Spi-B and PU.1 have also been shown to act synergistically in repressing pre-B-ALL in mice, 13, 35 further emphasizing the complex interplay within the Ets and IRF families in leukemia suppression.
Despite biochemical evidence that PU.1 interacts with IRF4/IRF8 in developing B cells, it remains unclear whether they functionally collaborate during B lymphopoiesis. To address this question, we generated mice that lack either PU.1 and IRF4 or PU.1 and IRF8 in the B-cell lineage. PU.1/IRF4 double-deficient mice show a partial developmental block beyond the pre-B-cell stage, while PU.1/IRF8-deficient mice have relatively normal early B-cell development but impaired late B-cell maturation in the BM. We recently showed that the loss of PU.1 and IRF8 negatively regulate immunoglobulin class-switching and plasma cell differentiation. 36 Strikingly, mice deficient for PU.1/IRF4 or PU.1/IRF8 developed pre-B-ALL at high frequency. Characterization of these pre-B-ALL showed that the Ets-IRF complexes directly regulate the expression of a number of known tumor suppressors including Spi-B, Ikaros and Blnk. We therefore conclude that Ets factor, PU.1, cooperate with IRF4 and IRF8 to suppress the formation of acute leukemia. Significantly, IRF4 and SPIB are commonly also downregulated in human B-ALL suggesting that the tumor suppressor activity of the ETS/IRF complex is also present in human pre-B cells. 
MATERIALS AND METHODS

Experimental animals
Cell culture
Cells were cultured in alpha-modified Eagle medium with 2 mM L-glutamine, 1 mM Na-pyruvate, 0.1 mM non-essential amino acids, 10 mM HEPES, pH 7.4, 100 μg/ml of streptomycin, 100 U/ml of penicillin, 50 μM β-mercaptoethanol (all supplements were from Sigma-Aldrich, Castle Hill, NSW, Australia), 10% heat-inactivated fetal calf serum and 2% IL-7 supernatant.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). A Student's t-test with two-tailed distributions for two samples with equal variance was used.
Please also see the Supplementary Information section for a more detailed materials and methods description and animal numbers used for each experiment.
RESULTS
Overlapping of binding sites between PU.1, IRF4 and IRF8 PU.1 can either bind to canonical Ets sites or in complex with IRF4 and IRF8 at composite EICE sites. To determine the global binding site pattern for PU.1, IRF4 and IRF8, we performed chromatin immunoprecipitation sequencing experiments for all three transcription factors in pro-B cells. Approximately half of the PU.1-binding was detected at EICE sites together with either Irf4 or Irf8 and, as expected, the other half of binding sites being canonical ETS sites (Figures 1a-d ). In addition, we compared the transcriptome of wild-type pro-B cells to PU.1, IRF4 and IRF8-deficient pro-B cells. Interestingly, only few genes were found to be differentially expressed in the single deficient B-cell progenitors, indicating redundant function of these three factors in early B-cell development (Figure 1e ). In summary, this data provides strong evidence for the relevance of the cooperative binding of PU. Figures 1B and D-G) . Strikingly, the combined loss of PU.1/IRF8 resulted in a further reduction in transitional and recirculating B cells compared with that observed in single mutant mice (Supplementary Figures 1B, F and G Supplementary Figures 2A and B) . Pro-B cells were not affected by the loss of either IRF4 and slightly increased, although not statistically significantly, in the absence of IRF8 expression ( Figure 3d and Supplementary Figure 2C ). The number of pre-B cells remained similar in PU.1/IRF8 DKO (Supplementary Figure 2C) . In our analysis of the pre-B-cell compartment, we noted that IRF4 loss lead to the absence of CD25 expression (Figure 3b ). chromatin immunoprecipitation sequencing revealed that IRF4 directly binds the promoter and an enhancer region between exons 1 and 2 of the Il2ra gene in pro-B cells, suggesting that IRF4 directly regulates the expression of CD25 in pre-B cells (Figure 3c ). Pre-B cells were therefore subsequently identified as B220 + CD19 + cKit − IgM − (Figure 3a) . The presence of pre-B cells was independently confirmed by analyzing the expression of CD43 (Supplementary Figure 3) . Pre-B-cell numbers were significantly increased in the absence of PU.1 and IRF4 when compared with wild-type pre-B cells (Figure 3e ). PU.1 and IRF4 mutant B cells are hyper-responsive to IL-7 Increased IL-7-dependent proliferation in vitro was previously reported for IRF4/IRF8 double-deficient pre-B cells. 15 To test whether altered responsiveness to IL-7 is involved in the expansion of B-cell progenitor cells observed in the absence of PU.1, IRF4 and IRF8, B220 + cells (predominantly pre-B cells) were isolated from the BM of mutant and wild-type mice, and cultivated in the presence of IL-7. Wild-type pre-B cells underwent a small transient proliferative response (Figure 4a) . Interestingly, cells lacking IRF4, with or without PU.1, had a higher proliferative response to IL-7 and continued to proliferate strongly throughout the experiment (32 days). In contrast, cells lacking PU.1, IRF8 or both factors proliferated similarly to wild-type cells in this assay (Figure 4a ). Although PU.1 has been implicated in regulating the Il7r gene, 40 no differences in surface IL-7Rα expression was observed on small and large pre-B cells from mice lacking IRF4, with or without PU.1 (Figure 4b ). This suggests that changes in the expression of IL-7Rα did not account for the hyper-responsiveness to IL-7.
The pre-B-cell receptor (pre-BCR) is usually only transiently detectable on the surface of wild-type pre-B cells. However, double deficiency in IRF4/IRF8 resulted in increased surface pre-BCR expression. 15 To examine how the combined loss of PU.1 and IRF4 impacts on this process, we examined pre-BCR expression on BM pre-B cells. Although no difference was observed in the number of pre-BCR + cells between wild-type, PU.1, and IRF4 singularly deficient mice, the number of pre-BCR + cells was increased significantly with the loss of one or both PU.1 alleles in the context of IRF4 deficiency (Figure 4c ). Taken together, these data demonstrate that the complex of PU.1 and IRF4 is an important regulator of IL-7 responsiveness and pre-BCR signaling, the major pathways that are active in pre-B cells. P-values compare the indicated groups using a paired t-test (two-tailed). *P o0.05, **P o0.005, ***P o0.0005. Table 1 ). In keeping with the literature, 32 we did not observe any leukemia in mice lacking IRF4 alone, although some individuals had to be euthanized due to manifestations of the known immune deficiencies present in these mice (Figure 5b) .
Flow cytometric analysis showed that the majority of splenic B cells in clinically ill mice consisted of CD19 + B220
− B cells, although in some cases, we also observed CD19 + B220
+ cells (Figure 6a ). The splenic cells could be cultured with IL-7 for more than 2 weeks to enrich for CD19 + leukemic cells (Figure 6a, lower) . The lack of B220 expression in PU.1-deficient cells was consistent with a previous report that PU.1 is required to activate Ptprc (Cd45), which codes for B220 in B cells. 11, 12, 41 However, it is noteworthy, that the vast majority of PU.1-deficient pre-leukemic B cells expressed B220 (Figure 2 and Supplementary Figure 1) . The reason for this discrepancy is currently not known, but it is consistent with our previous report that CD45 expression was also lost on PU.1-deficient acute myeloid leukemia cells. 20 Tumor cells from all genotypes expressed IL-7Rα and could be continuously grown in vitro in medium supplemented with IL-7 ( Figure 6a (Figure 3a) . (c) BM cells of each genotype were isolated and analyzed on the pro/pre-B cells (gated as in Figure 3a) for pre-BCR expression levels using an antibody that detects a conformational epitope of the pre-BCR but not with surrogate light-chain, λ5, or VpreB in the absence of IgH. A simplified genotype nomenclature is shown below the graphs with symbols representing the existence of two (+), one (+/ − ) or no ( − ) functional alleles for the indicated genes. The full genotypes are presented in the same order as in Figure 2a . The data in a and c are mean ± s.d. between 3 to 8 mice per genotype. P-values compare the indicated groups using a paired t-test (two-tailed). *Po 0.05, **Po 0.005, ***Po0.0005. ns, not significant. The cross symbol indicates the death of the cells growing in culture.
IgM, indicative of mature B cells, PU.1/IRF4 and PU.1/IRF8 DKO tumor cells expressed low amounts of IgM and even less Igκ on their surface suggestive of a pre-B-cell phenotype (Figure 6b ). PCR analysis for VDJ rearrangements of the Igh loci showed that all leukemic samples from PU.1/IRF8 DKO mice were monoclonal, and rearranged specifically the common V H J558 variable region. In keeping with very rapid onset PU.1/IRF4 DKO leukemias, these exhibited predominantly oligoclonal Igh rearrangements (Figure 6c ). Western blot analysis confirmed that the leukemic cells expressed IgM protein but not Igκ (Figure 6d ). Taken together, these results suggested that PU.1/IRF-deficient tumors display a pre-B-ALL phenotype. Loss of a single copy of PU. Blnk, Spi-B and Ikaros expression is reduced in PU.1/IRF-deficient leukemia Blnk is an intracellular adapter protein that has an important role in pre-BCR signaling and acts as a tumor suppressor of pre-B-ALL in mice and humans. 26, 42, [44] [45] [46] [47] Recently, Blnk was reported to be activated by PU.1 and Spi-B. 13, 35 The transcription factor Ikaros, encoded by the Ikzf1 gene, has a crucial role in early B-cell development 16, 48, 49 and pre-BCR signaling, [50] [51] [52] and its gene is 
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ETS and IRF factors control B-cell development SHM Pang et al mutated at a high frequency in pediatric pre-B-ALL. 42, 53, 54 Determination of PU.1, IRF4 and IRF8 binding sites in pro-B cells using chromatin immunoprecipitation sequencing showed that all three transcription factors bound to the promoter and/or enhancer regions of Blnk, Spib and Ikzf1, indicating that PU.1/IRF complexes potentially regulate the expression of these genes (Figures 7a-c, right) . Indeed, the expression of all three transcripts was significantly reduced in PU.1/IRF-deficient pre-B-ALL samples. Importantly, Blnk, Spib and Ikzf1 were already expressed at reduced levels in non-leukemic PU.1/IRF4 DKO pre-B cells when compared with wild-type pre B cells, indicating that PU.1, together with IRF4, directly regulates the expression of these genes ( Figure 7 ). The loss of one allele of PU.1 in Irf4 −/− mutant mice was sufficient to reduce the expression of all three target genes ( Figure 7 ). In contrast, there was no difference in the expression levels of Blnk, Spib and Ikzf1 in non-leukemic PU.1/IRF8 DKO pre-B cells when compared with wild-type pre B cells (Figure 7) . These results suggest that PU.1, IRF8 and IRF4 directly activate the transcription of Blnk, Spib and Ikzf1. Given that these genes are known tumor suppressor genes in mouse and human pre-B-ALL, it is likely that reduced expression of these genes contributes to the formation of pre-B-ALL in PU.1/IRF-deficient mice. IRF4 and SPI-B expression are reduced in human B-ALL Direct sequence mutations in IRF4, IRF8, SPIB or PU.1 (SPI1) in human B-ALL are rare. 25, 26 To examine the expression of these factors in human B-ALL, we have interrogated a public microarray data set derived from a large sample cohort (n = 486 (ref. 26)), representing multiple clinical subtypes, and compared this with the expression of these factors in CD10 + CD19 + pre-B cells and CD34 + hematopoietic progenitors derived from healthy donors (Figure 8c ). Although the expression of IRF8 and PU.1 (SPI1) was showed high variability across all samples, the expression levels of both IRF4 and SPIB were reduced in all B-ALL subtypes compared with normal pre-B cells (Figure 8c ). This data is consistent with the tumor suppressor function of IRF4 and the reduced Spib expression we describe here in mouse B-ALL ( Figure 7 ) and suggest a conserved role of the Ets-IRF-binding activity in preventing B-ALL in both species.
DISCUSSION
Although the Ets-IRF DNA-binding complex that recognizes an EICE consensus sequence was first described in B cells, 1, 4 its importance relative to isolated Ets and IRF binding sites has not been clearly deciphered. Here we demonstrate that around half of the PU.1-binding is at EICE site indicating an important role of PU.1/IRF complexes in early B-cell development. Despite a requirement for PU.1 in generating B cells from early hematopoietic progenitors, 9, 40, 55 the function of this factor after commitment to the B-cell lineage remains elusive. PU.1 is expressed at a uniform low level in B cells 37 and conditional mutagenesis demonstrated that B-cell development is largely normal in its absence.
11,12 PU.1 may have a role in the divergence of B1 B cells from the conventional (B2) B-cell lineage, as PU.1-deficient or hypomorphic B2 cells adopted a B1-like phenotype over time. 12, 56 One possible explanation for the minimal impact of PU.1 loss in B cells is the co-expression in B cells of the most related Ets protein in the mammalian genome, Spi-B. This hypothesis is strongly supported by the recent finding that PU.1/Spi-B DKO mice show a differentiation block at the pre-B-cell stage and develop pre-B-ALL at high frequency. 13 Strikingly, we show in this study that Spi-B expression was also markedly reduced in the absence of PU.1 and IRF4 or IRF8, and reintroduction of Spi-B inhibited the proliferation of leukemic cell lines.
IRF proteins have also been implicated in B-cell development. Both IRF4 and IRF8 are expressed from the pro-B-cell stage of differentiation, where they are under the control of Pax5. 57 There is clear evidence for a synergy between IRF4 and IRF8 in B cells as DKO B cells show a developmental arrest at the pre-B-cell stage due to a failure to rearrange Ig light-chain genes. [14] [15] [16] [17] We found that PU.1/IRF4 DKO B cells showed a partial developmental block at the transition from pre-B cells to immature B cells. In contrast, the combined absence of PU.1 and IRF8 allowed a normal transition to the IgM + immature B-cell stage. PU.1/IRF8 DKO mice did, however, show a strong decrease of recirculating mature B cells in the BM and a twofold reduction in follicular B cells (data not shown). Care must be taken in interpreting these findings as the PU.1/IRF4 DKO model utilized Mb1-Cre to delete the floxed PU.1 allele in B cells, while the PU.1/IRF8 DKO strain used Cd19-Cre. As Mb1-Cre fully deletes at the pro-B-cell stage, 39,58 while we and others have shown that Cd19-Cre deletion is partial at the pre-Bcell stage (~80% deletion of PU.1 (refs 11,13) ) and only deletes fully in B220 + IgM int immature B cells. Nevertheless, single deficiency of PU.1 using either Cd19-Cre 11 or Mb1-Cre (data not shown) allows normal BM B-cell development. Intriguingly, pre-B cells from all IRF4 mutant mice were highly proliferative in response to IL-7, regardless of the presence of PU.1. This recapitulated the results obtained from studies by Lu et al. 15 using IRF4/IRF8 DKO mice. 15 Although this hyperproliferation may be an important component of the tumor suppressor activity of IRF4, it is not sufficient to explain the leukemic potential of the cells, as IRF4 deficiency alone does not result in pre-B-ALL. IRF4 loss instead requires cooperating oncogenic events, such as BCR-ABL or constitutive c-Myc expression. 32, 33 Lu et al. 15 also found that IRF4/IRF8 DKO pre-B cells expressed a higher amount of the pre-BCR. 15 Interestingly, while the pre-BCR was expressed on the cell surface at a similar frequency in wild-type and Irf4 −/− B cells, we observed a striking increase in the level of pre-BCR in developing pre-B cells in PU.1/IRF4 DKO and PU.1 fl/+ Irf4 −/− pre-B cells, which may contribute to the large increase leukemogenesis when both PU.1 and Irf4 are mutated (see below).
The most striking aspect of this study is that all PU.1/IRF DKO mice develop pre-B-ALL that appears similar to the leukemia reported from PU.1/Spi-B DKO mice. 13 The different genetic models that we have utilized varied in that the incidence of leukemia was greatly accelerated in PU.1/IRF4 DKO mice, compared with the PU.1/IRF8 DKO or single PU.1 knockout strains. In keeping with this, PU.1/IRF4 DKO tumors were oligoclonal, while PU.1/IRF8 DKO tumors were monoclonal. Interestingly, the early onset of morbidity rate correlates with the loss of single PU.1 or Irf4 alleles, suggesting a dose-dependent effect. This effect appeared to be caused by genuine haploinsufficiency as we have not detected any evidence of loss of heterozygosity in PU.1 or Irf4 heterozygous mice.
Our molecular studies did not reveal any evidence for transcriptional cross-regulation of PU.1, IRF4 and IRF8. However, a candidate approach based on quantitative PCR and chromatin immunoprecipitation sequencing analyses revealed that the tumor suppressor genes, Blnk, Spib and Ikzf1, were direct targets of all three factors. Blnk and Ikzf1 are well known to promote early B-cell differentiation by controlling pre-BCR signaling 46, [50] [51] [52] 59 and to suppress pre-B-ALL in both mice and humans, 26, 42, 46, 47, 53, 54 although re-expression of Blnk in the leukemic cells in vitro did not alter the cell growth rates. Little is known about the role of SPIB in human acute leukemia, recent studies using PU.1/Spi-B DKO mice showed a high incidence of pre-B-ALL. 13 In keeping with this, overexpression of Spi-B, and to a lesser extent Ikaros, inhibited the growth of our leukemic cell lines in vitro, thus acting as classical tumor suppressors.
Given the complex genetic interactions described here in mice that have lost expression of several tumor suppressors, it might be predicted that PU.1, IRF4 and IRF8 are not likely candidates to singularly act as drivers of human leukemogenesis. In keeping with this prediction there have only been sporadic reports of mutations in PU.1 (SPI1) and IRF8 in B-ALL. 25, 26 Our analysis of the gene expression data from a very large cohort of B-ALL samples revealed that low IRF4 and SPIB expression was frequent, while IRF8 and PU.1 expression showed high variability and no clear directional trend. SPIB has also recently been reported to be downregulated in the ETV6-RUNX1 subset of B-ALL, 28 which is a finding consistent with our data. These data raise the possibility that activity of the various Ets/IRF complexes may also be compromised in human B-ALL.
